Clin Osteol 2013; 18(4): 148-152

Vascular calcification - a 21st century epidemicReview articles

S. Boček

Vascular wall calcification is an active process with complex regulation. It is contributed to by numerous mechanisms also involved in bone mineralization. Population ageing, metabolic syndrome, chronic kidney disease and diabetes mellitus are accompanied by an inc­ reased prevalence of extraosseous calcification, mainly in the aortic valve region and arterial walls. There are five basic clinical mani­ festations of vascular calcification: calcific aortic valve stenosis, medial calcific sclerosis, intimal calcification in atherosclerosis, vascu­ lar calcification in chronic kidney disease and calcific uremic arteriolopathy. These types of calcification have a significant clinical impact. More than 2% of persons over 65 years are diagnosed with aortic valve stenosis of degenerative etiology. The amount of cal­ cium deposited in the stenotic aortic valve is the best marker of the rate of aortic valve disease progression. Vascular wall calcification decreases vascular elasticity and contributes to atherosclerotic macroangiopathy. This results in decreased tissue perfusion. Medial cal­ cific sclerosis, a typical vascular condition observed in type 2 diabetes, leads to a 3-fold increase in the risk of leg amputation. In de­ veloped countries, the costs of management of the diabetic foot are currently equal to those associated with treatment of osteoporotic fractures.

Keywords: vascular calcification, atherosclerosis, calcification, osteoporosis

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boček S. Vascular calcification - a 21st century epidemic. Osteologický bulletin. 2013;18(4):148-152.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Murphy WA Jr, Nedden Dz D, Gostner P, Knapp R, Recheis W, Seidler H. The iceman: discovery and imaging. Radiology 2003;226:614-629. Go to original source...
    2. Lee JS, Morrisett JD, Tung C-H. Detection of Hydroxyapatite in Calcified Cardiovascular Tissues. Atherosclerosis 2012;224:340-347. Go to original source...
    3. Bostrom KI, Rajamannan NM, Towler DA The regulation of valvular and vascu­ lar sclerosis by osteogenic morphogens. Circ Res 2011;109:564-577. Go to original source...
    4. Shao JS, Cheng SL, Sadhu J, Towler DA Inflammation and the osteogenic regu­ lation of vascular calcification: a review and perspective. Hypertension. 2010; 55:579-592. Go to original source...
    5. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct pat­ terns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489-494. Go to original source...
    6. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL. Lipid oxidation products have opposite effects on calcifying vas­ cular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997;17:680-687. Go to original source...
    7. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and pro­ tection? Circulation 2007;116:2782-2785. Go to original source...
    8. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcifi­ cation. A neglected harbinger of cardiovascular complications in non-insulin-de­ pendent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978-983. Go to original source...
    9. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-1724. Go to original source...
    10. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-450. Go to original source...
    11. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA Msx2 promotes cardiovascular calcification by activating paracrine Wnt sig­ nals. J Clin Invest 2005;115:1210-1220. Go to original source...
    12. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res 2007;75:640-648. Go to original source...
    13. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006;1084:89-117. Go to original source...
    14. Carrington A, Abbott C, Griffiths J, Jackson N, Johnson S, Kulkarni J et al. Peripheral vascular and nerve function associated with lower limb amputation in people with and without diabetes. Clin Sci (Lond) 2001;101:261-266. Go to original source...
    15. Rajamannan N, Bonow R, Rahimtoola S. Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med 2007;4:254-262. Go to original source...
    16. Rajamannan N, Subramaniam M, Rickard D, Stock S, Donovan J, Springett M et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-2184. Go to original source...
    17. Moura L, Ramos S, Zamorano J, Barros I, Azevedo L, Rocha-Goncalves F et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561. Go to original source...
    18. Teo KK, Corsi DJ, Tam JW, Dumesnil JG, Chan KL. Lipid lowering on progres­ sion of mild to moderate aortic stenosis: meta-analysis of the randomized place­ bo-controlled clinical trials on 2344 patients. Can J Cardiol 2011;27:800-808. Go to original source...
    19. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004;95:560-567. Go to original source...
    20. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-772. Go to original source...
    21. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth musc­ le cells undergo vesicle-mediated calcification in response to changes in extracel­ lular calcium and phosphate concentrations: a potential mechanism for accelera­ ted vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-2867. Go to original source...
    22. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, JahnenDechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-a in in­ hibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-2930. Go to original source...
    23. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-1951. Go to original source...
    24. Savica V, Bellinghieri G, Monardo P, Muraca U, Santoro D. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney di­ sease: questions, myths and facts. J Nephrol 2013;26:456-464. Go to original source...
    25. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-1277. Go to original source...
    26. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998;32:384-391. Go to original source...
    27. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous ar­ terioles with infarcts of the subcutis and skin (calciphylaxis) in chronic renal failure. Am J Kidney Dis 2000;35:588-597. Go to original source...
    28. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, dia­ gnosis, and treatment. Semin Dial 2002;15:172-186. Go to original source...
    29. Griethe W, Schmitt R, Jurgensen JS, Bachmann S, Eckardt KU, Schindler R. Bone morphogenic protein-4 expression in vascular lesions of calciphylaxis. J Nephrol 2003;16:728-732. Go to original source...
    30. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001;37:1267-1276. Go to original source...
    31. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate tre­ atment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006;1:1161-1166. Go to original source...
    32. Meissner M, Kaufmann R, Gille J. Sodium thiosulphate: a new way of treatment for calciphylaxis? Dermatology 2007;214:278-282. Go to original source...
    33. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challen­ ge. J Nephrol 2011;24:142-148. Go to original source...
    34. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vita­ min K in rats. Blood 2007;109:2823-2831. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.